Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer

被引:11
|
作者
Ueki, Nami [1 ]
Matsuo, Yukinori [1 ]
Shibuya, Keiko [2 ]
Nakamura, Mitsuhiro [1 ]
Narabayashi, Masaru [1 ]
Sakanaka, Katsuyuki [1 ]
Norihisa, Yoshiki [1 ]
Mizowaki, Takashi [1 ]
Hiraoka, Masahiro [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Sakyo Ku, Kyoto 6068507, Japan
[2] Yamaguchi Univ, Grad Sch Med, Dept Therapeut Radiol, Ube, Yamaguchi 7558505, Japan
基金
日本学术振兴会;
关键词
lung cancer; stereotactic body radiation therapy; dose-volume metrics; heterogeneity correction; local control; PHASE-II TRIAL; INHOMOGENEITY CORRECTIONS; RADIOTHERAPY; ALGORITHM;
D O I
10.1093/jrr/rrs084
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The purpose of this study is to evaluate the dose-volume metrics under different heterogeneity corrections and the factors associated with local recurrence (LR) after stereotactic body radiation therapy (SBRT) for non-small-cell lung cancer (NSCLC). Eighty-three patients who underwent SBRT for pathologically proven stage I NSCLC were reviewed retrospectively. The prescribed dose was 48 Gy in four fractions at the isocenter (IC) under heterogeneity correction with the Batho power law (BPL). The clinical plans were recalculated with Eclipse (Varian) for the same monitor units under the BPL and anisotropic analytical algorithm (AAA) and with no heterogeneity correction (NC). The dose at the IC, dose that covers 95% of the volume (D95), minimum dose (Min), and mean dose (Mean) of the planning target volume (PTV) were compared under each algorithm and between patients with local lesion control (LC) and LR. The IC doses under NC were significantly lower than those under the BPL and AAA. Under the BPL, the mean PTV D95, Min and Mean were 8.0, 9.4 and 7.4% higher than those under the AAA, and 9.6, 9.2 and 4.6% higher than those under NC, respectively. Under the AAA, all dose-volumetric parameters were significantly lower in T1a patients than in those with T1b and T2a. With a median follow-up of 35.9 months, LR occurred in 18 patients. Between the LC and LR groups, no significant differences were observed for any of the metrics. Even after stratification according to T-stage, no significant difference was observed between LC and LR.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [21] Influence of target dose heterogeneity on dose sparing of normal tissue in peripheral lung tumor stereotactic body radiation therapy
    Zhigong Wei
    Xingchen Peng
    Yan Wang
    Lianlian Yang
    Ling He
    Zheran Liu
    Jingjing Wang
    Xiaoli Mu
    Ruidan Li
    Jianghong Xiao
    Radiation Oncology, 16
  • [22] The influence of heterogeneity corrections on tumor and normal lung dosimetry in stereotactic body radiation therapy for lung cancer treatment
    Ding, M
    Kananagh, BD
    Schefter, T
    Stuhr, K
    Newman, F
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S511 - S512
  • [23] Escalated Maximum Dose in the Planning Target Volume Improves Local Control in Stereotactic Body Radiation Therapy for T1-2 Lung Cancer
    Inagaki, Takaya
    Doi, Hiroshi
    Ishida, Naoko
    Ri, Aritoshi
    Tatsuno, Saori
    Wada, Yutaro
    Uehara, Takuya
    Inada, Masahiro
    Nakamatsu, Kiyoshi
    Hosono, Makoto
    Nishimura, Yasumasa
    CANCERS, 2022, 14 (04)
  • [24] Dose-Volume Analysis in a Phase II Study of Stereotactic Body Radiation Therapy for cT1N0M0 Non-small Cell Lung Cancer (JCOG0403): Impact of Dose Calculation Algorithm with Heterogeneity Correction on Local Control in Operable Patients
    Matsuo, Y.
    Ishikura, S.
    Shibata, T.
    Kokubo, M.
    Karasawa, K.
    Kozuka, T.
    Tateoka, K.
    Anai, S.
    Nagata, Y.
    Hiraoka, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S855 - S855
  • [25] Radiation Induced Rib Fractures after Hypofractionated Stereotactic Body Radiation Therapy: The Risk Factors and Dose-Volume Relationship
    Asai, K.
    Shioyama, Y.
    Ohga, S.
    Nonoshita, T.
    Yoshitake, T.
    Ohnishi, K.
    Terashima, K.
    Matsumoto, K.
    Hirata, H.
    Honda, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S136 - S137
  • [26] Development of Biomechanical Models to Describe Dose-Volume Response to Liver Stereotactic Body Radiation Therapy (SBRT) Patients
    McCulloch, M.
    Polan, D.
    Feng, M.
    Lawrence, T.
    Ten Haken, R.
    Brock, K.
    MEDICAL PHYSICS, 2015, 42 (06) : 3653 - 3653
  • [27] Impact of Overall Treatment Time on Local Control After Stereotactic Body Radiation Therapy for Lung Cancer
    Matsuo, Y.
    Ueki, N.
    Miyagi, K.
    Yoshimura, M.
    Sakanaka, K.
    Norihisa, Y.
    Mizowaki, T.
    Shibuya, K.
    Nagata, Y.
    Hiraoka, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S551 - S551
  • [28] Radiation-Induced Rib Fractures After Hypofractionated Stereotactic Body Radiation Therapy: Risk Factors and Dose-Volume Relationship
    Asai, Kaori
    Shioyama, Yoshiyuki
    Nakamura, Katsumasa
    Sasaki, Tomonari
    Ohga, Saiji
    Nonoshita, Takeshi
    Yoshitake, Tadamasa
    Ohnishi, Kayoko
    Terashima, Kotaro
    Matsumoto, Keiji
    Hirata, Hideki
    Honda, Hiroshi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : 768 - 773
  • [29] Dose-Volume Histogram (DVH) Analysis of Stereotactic Body Radiation Therapy (SBRT) Treatment of Pancreatic Cancer: A Focus on Treatment Delivery and Duodenal Dose Constraints
    Goldsmith, C. S.
    Rice, L.
    Edwards, A.
    Price, P.
    Cross, T.
    Loughlin, S. A.
    Cowley, I. R.
    Plowman, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E170 - E170
  • [30] STEREOTACTIC BODY RADIATION THERAPY FOR LIVER METASTASES: INFLUENCE ON LOCAL CONTROL OF TARGET SURROGATES FOR ALIGNMENT AND DOSE LEVELS
    Casamassima, F.
    Masciullo, S.
    Menichelli, C.
    Masi, L.
    Doro, R.
    Bonucci, I.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S399 - S399